Our Visionaries

What makes us market leaders

We bring the right people together to make extraordinary things happen in the markets we serve. We’re scientists, strategists, business leaders and lateral thinkers. Our expertise is in oxidation catalysis but our entrepreneurial spirit drives our success.

It is this coming together of highly technical, commercial and operational minds that makes us unique. We don’t just have an R&D vision, we see it through from the lab to industry and every important stage in-between and beyond.

Our people are passionate about pioneering positive change in industry and united in their goal to harness the full potential of catalysis to make positive change possible, in as many markets as possible.

  • Paul Smith

    CEO

    Strategist

    Converging the technical and commercial, Paul is the strategist steering our success in new sectors, while maximising our reach in existing markets.

    A chemist at heart, Paul brings more than 35 years of industry experience to his role as Chief Executive Officer. He has an enviable track record in working with large multi-national chemical companies, including Albright & Wilson, Brent International and Elementis PLC, excelling in business leadership and board level roles before pursuing his venture capital career.

    Insightful investor

    As a keen investor in innovative chemical technology companies, Paul’s in-depth industry knowledge, academic background and ambitious leadership qualities are invaluable. He has orchestrated several highly profitable exits for investors and most notably led the sale of Rahu Catalytics in 2011 to OM Group Inc. – a Wall Street listed US specialty chemicals player.

    Champion of change

    Today, he is hugely passionate about delivering on Catexel’s full potential in the current markets served as well as finding new territories where its chemistry can make an important positive change to industrial processes.

  • Glenn Fletcher

    COO

    Commercial custodian

    An important bridge between the company’s technical and commercial interests, Glenn is the champion and custodian of the ecosystem that underpins Catexel.

    Concerned with supply chain control he has engineered a network of expert partners that make bespoke chemical synthesis possible on an industrial scale. He has sourced, negotiated and secured a solid manufacturing, logistics and regulatory hub that has helped Catexel’s chemistry conquer worldwide industrial challenges.

    Value creator

    A Chartered Accountant (PwC) by training, and with 25 years in senior finance and operation roles in the chemicals and fibres sectors (Courtaulds plc, Akzo Nobel BV and Lenzing AG), Glenn plays a vital financial and operational role on the board. His strengths are building and creating value, and securing future growth for stakeholders, as well as ensuring the more immediate concerns of financing, commercial contracts, security of supply, quality assurance and regulatory compliance are addressed for the business and its customers.

    High growth business leader

    His finance background and industrial experience have included exposure to M&A, finance markets, private equity and venture capital activities. This has helped shape Glenn’s contribution to building and realising value within high growth businesses, now including Catexel. He also played a pivotal role in the successful sale of Rahu Catalytics, alongside Paul Smith and Dr Ronald Hage in 2011.

  • David Greensmith

    Chairman and Non-Executive Director

    Senior business lead

    Industry expert, insightful and independent, David is a grounding influence and an inspirational business lead.

    David has held senior positions in the chemicals and pharma industry for 40 years. As CEO, Managing Director and COO of some of the sector’s most respected firms – including ICI then Zeneca Specialties – he has seen and implemented enormous change that has led to commercial success.

    Private equity expert

    His step into the Private Equity world came during his time at Avecia – a broad based specialty chemical business covering multiple industries. As COO he helped build the business up through a series of acquisitions and organic growth before leading the divestment of 12 divisions – one of which was the sale of the Electronics Materials subsidiary to FujiFilm. At this point, David was invited to take the strategic lead at FujiFilm, where he dedicated two years to integrating the Inkjet and Industrial Colorants businesses. Since 2008 he’s been acting as Chair and Consultant to several highly successful chemical company start-ups, including Catexel, to fast-track commercial success through leveraging stand-out technology.

    Chair and consultant

    Since 2008 David has played an important part in helping carve out Catexel’s strength of position on the chemicals world stage as one of the most interesting PE ventures of recent times.

  • Ronald Hage

    CTO

    Expert in oxidation catalysis

    A hugely respected researcher in his field, Ronald’s deep understanding of catalytic behavior is building a pipeline of present day and future potential for our exclusive technology platforms.

    Ronald is a world leading expert in oxidation catalysis.

    Leading academic

    With a PhD in inorganic chemistry and an extensive career in research and development, he has achieved international industry acclaim for developing breakthrough bleaching technologies based on manganese and iron oxidation catalysis. Initially working with Unilever to identify opportunities in detergent applications, he is now exploring the full scientific and commercial potential of a suite of highly stable, highly active catalysts, exclusive to Catexel.

    Industry speaker

    In his capacity as Chief Technology Officer at Catexel, Ronald is regularly invited to speak at global conferences and events and maintains close links with the University of Groningen, as well as various other centres of scientific excellence – supporting through guest lecturer appearances and mentoring PhD students.

    Serial patent generator

    Externally Ronald sits on the editorial advisory board of a number of academic journals and has contributed to 105 peer reviewed articles during his two decades of research and development success, during which he has published 88 patents to-date.

    Along with Paul Smith and Glenn Fletcher, Ronald led the successful exit of Rahu Catalytics to OM Group Inc. in 2011.